The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citationOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Alley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Capturing complex 3D tissue physiology in vitro
Griffith, L. G., & Swartz, M. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1858 · Cited by 2,290
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Yang, W. S., & Stockwell, B. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.010 · Cited by 1,876
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Self-citationVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Compensation mechanism in tumor cell migration
Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Bröcker, E.-B., & Friedl, P. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209006 · Cited by 1,391
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Three-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336
Abbott, A. (2003) · Nature · doi:10.1038/424870a · Cited by 1,234
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Sahai, E., & Marshall, C. J. (2003) · Nature Cell Biology · doi:10.1038/ncb1019 · Cited by 1,147
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797
The National Cancer Institute: cancer drug discovery and development program.
Grever, M. R., Schepartz, S. A., & Chabner, B. A. (1992) · PubMed · Cited by 722
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
The Increasing Complexity of the Cancer Stem Cell Paradigm
Rosen, J. M., & Jordan, C. T. (2009) · Science · doi:10.1126/science.1171837 · Cited by 698
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., del Grammastro, M., Sciarrotta, M. G., Buttitta, F., Incarbone, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1635 · Cited by 557
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
Three-dimensional cell cultures: from molecular mechanisms to clinical applications
Mueller-Klieser, W. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.273.4.c1109 · Cited by 537
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Self-citationUnited States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Brock, A., Chang, H., & Huang, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2556 · Cited by 486
Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge?
Friedrich, J., Ebner, R., & Kunz-Schughart, L. A. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701727531 · Cited by 446
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Self-citationMulticellular spheroids: A review on cellular aggregates in cancer research
Mueller-Klieser, W. (1987) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00391431 · Cited by 434
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5084 · Cited by 429
Cohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Self-citationAntitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356
Self-citationKelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352
Maintenance of Normoglycemia in Diabetic Mice by Subcutaneous Xenografts of Encapsulated Islets
Lacy, P. E., Hegre, O. D., Gerasimidi-Vazeou, A., Gentile, F. T., & Dionne, K. E. (1991) · Science · doi:10.1126/science.1763328 · Cited by 345
In vivo cultivation of tumor cells in hollow fibers
Hollingshead, M. G., Alley, M. C., Camalier, R. F., Abbott, B. J., Mayo, J. G., Malspeis, L., & Grever, M. R. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00254-4 · Cited by 344
Nelson, C. M., & Bissell, M. J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.05.001 · Cited by 332
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 326
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
Neural Computing in Cancer Drug Development: Predicting Mechanism of Action
Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., Monks, A. P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., et al. (1992) · Science · doi:10.1126/science.1411538 · Cited by 312
Leukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Taking the Study of Cancer Cell Survival to a New Dimension
Jacks, T., & Weinberg, R. A. (2002) · Cell · doi:10.1016/s0092-8674(02)01229-1 · Cited by 304
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Clonogenic assay with established human tumour xenografts
Fiebig, H. H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 291
Yamori, T., Matsunaga, A., Sato, S., Yamazaki, K., Komi, A., Ishizu, K., Mita, I., Edatsugi, H., Matsuba, Y., Takezawa, K., et al. (1999) · PubMed · Cited by 264
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255
Dan, S., Tsunoda, T., Kitahara, O., et al. (2002) · PubMed · Cited by 246
Dagher, R., Cohen, M., Williams, G., et al. (2002) · PubMed · Cited by 237
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P., & Murray, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 234
A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes
Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y., Jiang, J., Yuza, Y., Classon, M., Haber, D. A., & Settleman, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.014 · Cited by 233
Self-citationA reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay
Friedrich, J., Eder, W., Castaneda, J., Doss, M., Huber, E., Ebner, R., & Kunz-Schughart, L. A. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107306839 · Cited by 227
Cisplatin as first-line therapy for metastatic breast cancer.
Sledge, G. W., Loehrer, P. J., Roth, B. J., & Einhorn, L. H. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1811 · Cited by 225
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
Peterson, J. K., & Houghton, P. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.003 · Cited by 223
Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., & Fojo, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117910 · Cited by 216
Marks, J. L., Gong, Y., Chitale, D., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 211
Proteasome inhibition in cancer: Development of PS-341
ADAMS, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90034-x · Cited by 209
Hazlehurst, L. A., Landowski, T. H., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206943 · Cited by 203
Frankel, A., Man, S., Elliott, P. J., Adams, J., & Kerbel, R. S. (2000) · PubMed · Cited by 201
Mechanisms of Disease: Cancer stem cells--targeting the evil twin
Trumpp, A., & Wiestler, O. D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1110 · Cited by 199
Eshleman, J. S., Carlson, B. L., Mladek, A. C., Kastner, B. D., Shide, K. L., & Sarkaria, J. N. (2002) · PubMed · Cited by 198
Khaitan, D., Chandna, S., Arya, M., & Dwarakanath, B. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-12 · Cited by 196
Serebriiskii, I., Castelló-Cros, R., Lamb, A., Golemis, E. A., & Cukierman, E. (2008) · Matrix Biology · doi:10.1016/j.matbio.2008.02.008 · Cited by 176
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Johnston, S. R. D., & Leary, A. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.7.985637 · Cited by 174
Update on NCI in vitro drug screen utilities
Holbeck, S. L. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.022 · Cited by 173
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Monks, A. P., Da, S., Johnson, G. S., Paull, K. D., & Sausville, E. (1997) · PubMed · Cited by 171
The response to chemotherapy of a variety of human tumour xenografts
Steel, G. G., Courtenay, V. D., & Peckham, M. J. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.1 · Cited by 167
Frankel, A., Buckman, R. A., & Kerbel, R. S. (1997) · PubMed · Cited by 166
Naasani, I., Seimiya, H., Yamori, T., & TSURUO, T. (1999) · PubMed · Cited by 155
Barbone, D., Yang, T., Morgan, J. R., Gaudino, G., & Broaddus, V. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709698200 · Cited by 149
Lanza, R., Butler, D. H., BORLAND, K. M., Staruk, J. E., Faustman, D. L., Solomon, B. A., Muller, T. E., Rupp, R. G., Maki, T., & Monaco, A. P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11100 · Cited by 148
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
Yamori, T. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0649-1 · Cited by 146
Affoué, M., Laurent, L., Ploton, D., Poupon, M., Jc, J., & Bobichon, H. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1014594825502 · Cited by 135
Howes, A. L., Chiang, G. G., Lang, E. S., Ho, C., Powis, G., Vuori, K., & Abraham, R. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0698 · Cited by 135
Relations between ph, oxygen partial pressure and growth in cultured cell spheroids
Carlsson, J., & Acker, H. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420515 · Cited by 131
Spheroids in radiobiology and photodynamic therapy
Dubessy, C., Merlin, J. M., Marchal, C., & Guillemin, F. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00085-8 · Cited by 128
Kaufman, B., Trudeau, M., Awada, A. H., Blackwell, K., Bachelot, T., Salazar, V., DeSilvio, M., WESTLUND, R. E., Zaks, T. Z., Spector, N. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70087-7 · Cited by 124
Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J., & Boyd, M. R. (1992) · PubMed · Cited by 119
Durand, R. E., & Olive, P. L. (2001) · Methods in cell biology · doi:10.1016/s0091-679x(01)64015-9 · Cited by 107
Shiwa, M., Nishimura, Y. H., Wakatabe, R., Fukawa, A., Arikuni, H., Ota, H., Kato, Y., & Yamori, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01520-1 · Cited by 105
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Nieto, J., Grossbard, M. L., & Kozuch, P. S. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0181 · Cited by 102
Ballangrud, Å., Yang, W., Charlton, D. E., McDevitt, M. R., Hamacher, K. A., Panageas, K. S., Ma, D., Bander, N. H., Scheinberg, D. A., & Sgouros, G. (2001) · PubMed · Cited by 98
McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R. J., Tam, A., Lee, D. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4327 · Cited by 97
Self-citationAntitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast Cancer
Liu, M., Howes, A. L., Lesperance, J., Stallcup, W. B., Hauser, C. A., Kadoya, K., Oshima, R. G., & Abraham, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4589 · Cited by 97
Guðjónsson, Þ., Rønnov‐Jessen, L., Villadsen, R., Bissell, M. J., & Petersen, O. W. (2003) · Methods · doi:10.1016/s1046-2023(03)00031-8 · Cited by 93
David, L., Dulong, V., Cerf, D. L., Cazin, L., LAMACZ, M., & Vannier, J. (2007) · Acta Biomaterialia · doi:10.1016/j.actbio.2007.08.012 · Cited by 93
Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic Agents
van Osdol, W. W., Myers, T. G., Paull, K. D., Kohn, K. W., & Weinstein, J. N. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.24.1853 · Cited by 85
Staquet, M. J., Byar, D. P., Green, S. B., & Rozencweig, M. (1983) · PubMed · Cited by 77
Nakatsu, N., Yoshida, Y., Yamazaki, K., Nakamura, T., Dan, S., Fukui, Y., & Yamori, T. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0234 · Cited by 76
Drexler, H. G., Fombonne, S., Matsuo, Y., Hu, Z.-B., Hamaguchi, H., & Uphoff, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401604 · Cited by 72
The National Cancer Chemotherapy Program
Frei, E. (1982) · Science · doi:10.1126/science.7046055 · Cited by 64
Scholz, C. C., Berger, D. P., Winterhalter, B. R., Henβ, H., & Fiebig, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90196-z · Cited by 62
Integrated analysis of breast cancer cell lines reveals unique signaling pathways
Heiser, L. M., Wang, N. J., Talcott, C., Laderoute, K. R., Knapp, M., Guan, Y., Hu, Z., Ziyad, S., Weber, B. L., Laquerre, S. G., et al. (2009) · Genome biology · doi:10.1186/gb-2009-10-3-r31 · Cited by 61
Dardousis, K., Voolstra, C., Roengvoraphoj, M., Sekandarzad, A., Mesghenna, S., Winkler, J., Ko, Y., Hescheler, J., & Sachinidis, A. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300003 · Cited by 54
Poland, J., Sinha, P. K., Siegert, A., Schnölzer, M., Korf, U., & Hauptmann, S. (2002) · Electrophoresis · doi:10.1002/1522-2683(200204)23:7/8<1174::aid-elps1174>3.0.co;2-o · Cited by 48
The use of GEM models for experimental cancer therapeutics
Gopinathan, A., & Tuveson, D. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000570 · Cited by 47
Why drugs fail: of mice and men revisited.
Takimoto, C. H. M. (2001) · PubMed · Cited by 42
Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA
Sausville, E. A., & Feigal, E. G. (1999) · Annals of Oncology · doi:10.1023/a:1008333901925 · Cited by 41
Identification of genes differentially expressed in V79 cells grown as multicell spheroids
Oloumi, A., Lam, W. L., Banáth, J. P., & Olive, P. L. (2002) · International Journal of Radiation Biology · doi:10.1080/09553000210122299 · Cited by 40
Gershenson, D. M., Burke, T. W., Morris, M., Bast, R. C., Guaspari, A., Hohneker, J. A., & Wharton, J. T. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5130 · Cited by 37
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
Feiler, H. S., Nora, B., Wang Nicholas, J., Zhi, H., Gerald, F., V, Sadanandam, A., Heiser Laura, M., Gibb William, J., Bhattacharya, S., Safiyyah, Z., et al. (2009) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.1186/1741-7015-7-77 · Cited by 37
Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.
Rossi, A., Gridelli, C., Gebbia, V., Rosati, G., Tortoriello, A., Maione, P., Borsellino, N., Rossi, N., Pisano, A., Colantuoni, G., et al. (2003) · PubMed · Cited by 34
McDermott, U., Sharma, S. V., & Settleman, J. E. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38023-3 · Cited by 31
Self-citationCetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William, W. N., Kim, E. S., & Herbst, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/ncponc1321 · Cited by 13
Cited by
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
“56 57 The development of effective treatments for liver cancer has been hindered by the shortage of 58 reproducible human models to assess the efficacy of candidate therapeutic agents [8].”
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931
Metadata
- Authors
- Sharma, S. V., Haber, D. A., & Settleman, J.
- Venue
- Nature Reviews Cancer
- Published
- 2010-03-19
- Volume
- 10
- Issue
- 4
- Pages
- 241-253
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2026548544
- Cited by
- 586
- References
- 152
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.